Objective: To evaluate whether early treatment with inhaled nitric oxide (iNO) will prevent newborns with moderate respiratory failure from developing severe hypoxemic respiratory failure (oxygenation index (OI)X40).
Introduction
Persistent pulmonary hypertension of the newborn (PPHN) is a serious condition that may accompany respiratory diseases such as meconium aspiration syndrome, pneumonia, respiratory distress syndrome and congenital diaphragmatic hernia. 1, 2 Despite the variety of causes, similar physiopathologic changes characterize this syndrome: a persistently raised pulmonary vascular resistance after birth, which leads to severe hypoxemia due to extrapulmonary shunting. This disease can progressively get worse, due to the fact that sustained hypoxia may injure pulmonary vasculature inducing remodeling and making it unresponsive to vasodilators. 3, 4 The sustained hypoxemia and the high oxygen concentrations, and elevated ventilator pressures/volumes needed to treat these infants, may lead to further lung injury and myocardial dysfunction. This sequence of events may result in death, an occurrence made more common in countries that do not have access to extracorporeal membrane oxygenation (ECMO), where mortality of this syndrome is between 10 and 40%. 1, 2, 5, 6 Inhaled nitric oxide (iNO) has been shown to be an effective treatment for PPHN. [7] [8] [9] [10] Several randomized clinical trials have shown that iNO significantly improves oxygenation and decreases the need of ECMO or incidence of death in near-term infants with hypoxic respiratory failure. [11] [12] [13] However, their response to iNO is not ideal and ranges between 50 and 60%. This may be due to the fact that in most studies, infants were critically ill, either fulfilling ECMO criteria (oxygenation index (OI) X 40) or had severe lung disease and vascular damage, and were unresponsive to therapy. It has been also shown that iNO may attenuate lung inflammation and pulmonary vascular remodeling in experimental lung-injured models. 14, 15 On the basis this information, we hypothesized that early treatment with iNO in newborns with moderate respiratory failure (OI between 10 and 30) and pulmonary hypertension would improve oxygenation and attenuate the development of severe hypoxemic respiratory failure (OI > 40).
Methods
This was a prospective, randomized controlled and unblinded trial performed in two neonatal intensive care units in Santiago, Chile between March 1997 and December 2003. This study was approved by the investigational review board of the Pontificia Universidad Católica de Chile School of Medicine and by the ethics committees of both hospitals. A written informed consent was obtained from the parents of all infants at the time of enrollment.
Study population
Near-term infants (X35 weeks gestation) with birth weights >2000 g and p48 h old were eligible for enrollment. We included 56 infants requiring mechanical ventilation with moderate hypoxemic respiratory failure with an OI between 10 and 30. This was calculated on two consecutive measurements of post-ductal arterial blood gases and after ventilatory support had been adjusted to achieve a PCO 2 < 60 mm Hg and pH > 7.25. All infants had a previous echocardiogram, which was negative for cardiac anomalies and had evidence of pulmonary hypertension. This was defined as a tricuspid insufficiency jet with an estimated systolic pulmonary artery pressure X2/3 of systemic systolic arterial blood pressure and/or evidence of right-to-left shunting through the foramen ovale or ductus arteriosus. Exclusion criteria included the presence of a life-threatening congenital anomaly, suspected or confirmed chromosomal abnormality, congenital heart disease, congenital diaphragmatic hernia and other forms of lung hypoplasia syndromes.
Protocol
Infants were randomized using sequenced sealed envelopes into two study groups:
(1) Early iNO group, which received iNO with conventional mechanical ventilation, and (2) Control group, which received conventional mechanical ventilation with 1. If condition of the patient deteriorated with the reduction of dose, the dose was increased to obtain the minimal dose necessary to keep oxygen saturations X88%. The new dose was maintained for at least 24 h. Attempts were made to discontinue iNO, if the patient had been stable on an iNO dose p5 p.p.m. and with an OI < 10 for 24 h. If this was not possible, iNO was continued for an additional 24 h.
Treatment failure was defined as a worsening in respiratory status during first 48 h of treatment based on an increase in the OI to >40. Patients in the Control group who reached an OI > 40 were treated with iNO. Infants in both groups who persisted with an OI >40 despite iNO were treated with high-frequency oscillatory ventilation (HFOV) and iNO. ECMO treatment was not available in Chile during the study period.
Inhaled nitric oxide was delivered using a 990 p.p.m. sealed tank (AGA Chile SA, Santiago, Chile/INO Therapeutics; Port Allen, LA, USA) and iNO and NO 2 levels were continuously measured by electrochemical cell analyzers (PAC II Analyzer; Draeger, Lü beck, Germany and NOxBox I; Bedfont, Rochester, England, UK). An indwelling arterial line was placed in all patients to monitor systemic arterial blood pressure and draw serial arterial blood gases at baseline, 4, 12 and 24 h and at least every 12 h thereafter while the patient was receiving iNO. Methemoglobin levels were also measured at baseline and every 24 h while the patient was on iNO. All these variables along with the clinical data of patients including pregnancy history and delivery, birth weight, age, and the presence of other complications of the neonatal period such as intraventricular hemorrhage, pneumothorax, chronic lung disease (defined as oxygen dependence for 28 or more days and an abnormal chest X-ray), were recorded on standardized forms and saved in a computer database.
Statistical analyses
Sample size was estimated based on previous data. 6 Assuming that 60% of Control group patients would develop an OI X 40, we calculated that approximately 54 patients would need to be enrolled to provide the study with 80% power to detect a reduction in treatment failure to 33% in the Early iNO group, with a type I error of 0.05. We conducted the analysis according to the intentionto-treat principle. Clinical and demographic characteristics were compared using the Student's t-test and analysis of variance for continuous variables with normal distribution, and Mann-Whitney test for independent samples for those with a not normal distribution. Categorical variables were compared using w 2 -test and if the expected number of observations was less than 5, Fisher's exact test was used instead. A P-value p0.05 was considered significant.
Results
A total of 56 newborns were enrolled in this study, 28 in each group. As seen in Table 1 , characteristics of infants did not differ iNO in newborns with moderate respiratory failure A González et al between the groups in terms of birth weight, age at randomization, condition at birth and the underlying respiratory diseases associated with their respiratory failure.
The baseline ventilatory and hemodynamic conditions were also similar between the Early iNO and Control groups at the time of enrollment ( Table 2 ). The infants required moderately high levels of conventional ventilatory support, with FiO 2 ranging between 0.75 and 1.
Acute changes in oxygenation
Infants assigned to the Early iNO group had a significant increase in PaO 2 from baseline, which led to a significant decrease in their OI: (mean ± s.d.) OI decreased from 22.2 ± 4.3 at baseline to 19.0 ± 7.2 at 4 h (P<0.05), which continued decreasing over time (Figure 1 ). In contrast, OI increased in the Control group and remained significantly higher than the Early iNO group during the first 48 h of study (P<0.01).
Treatment failure
Seven of 28 infants (25%) receiving early iNO and 17 of 28 infants (61%) on conventional therapy developed an OI >40 treatment failure (P<0.05). Of 17, 6 control patients who developed an OI>40 were successfully treated with iNO subsequently. Nine of the remaining eleven control patients and six of seven Early iNO patients who had an OI > 40 despite iNO responded with the addition of HFOV. One patient of the Early iNO group and two of the Control group died. Table 3 shows the respiratory outcomes of both groups: duration of mechanical ventilation was not significantly different, whereas duration of oxygen therapy was significantly lower among infants of the Early iNO group (P<0.03). This was confirmed with the survival analysis for the need of oxygen therapy, which was significantly higher over time in Control group (Figure 2 ).
Patients treated with iNO did not have elevated blood levels of methemoglobin or high levels of NO 2 in the ventilatory circuit. Also, there were no differences between the groups in the incidence of other neonatal complications such as bleeding and/or coagulation disorders, hypotension or infections. 
Discussion
The present study shows that early treatment with iNO in neonates with moderate hypoxemic respiratory failure increases oxygenation and decreases the probability of developing severe PPHN/respiratory failure (OI>40). The observed improvement in oxygenation with iNO therapy is consistent with the results of several randomized controlled studies. [11] [12] [13] The novel aspect of this trial is the early use of iNO in the disease's course in centers without ECMO availability, preventing the development of severe respiratory failure in most treated infants. This reduction in PPHN severity may decrease mortality and respiratory sequelae in patients with respiratory failure in places where ECMO is not available. As the observed mortality was low in both groups, unfortunately this study was not powered to confirm this point. Until now, most published reports have not shown a decrease in mortality with iNO, possibly this can be explained because ECMO was used in infants when iNO failed.
Along with their oxygenation improvement, infants who received early iNO required less time with oxygen supplementation and therefore their oxygen exposure was reduced. It is possible that this strategy of early iNO use may decrease lung damage and the severity of chronic lung disease in infants with moderate respiratory failure. Most studies have not shown a clear benefit of iNO in long-term respiratory outcomes. In the majority of these studies, treated infants were sicker, enrolled later in the disease course and all of them had ECMO as a rescue therapy when iNO failed. In this study however, ECMO was not available and therefore those infants whose oxygenation did not improve remained either on conventional or HFOV with high settings and elevated oxygen concentrations for longer periods of time.
There are few studies that have evaluated a relatively 'early' iNO use strategy. Davidson et al. 16 did not find clear differences in the length of oxygen supplementation or mechanical ventilation; however the studied infants seem sicker and ECMO was available. The Franco-Belgium Collaborative NO Trial Group 17 showed a decrease in length of mechanical ventilation and a lower proportion of infants requiring oxygen at 28 days when iNO was used in near-term infants younger than 7 days with moderate respiratory failure (OI of 15 to 40). Sadiq et al. 18 compared iNO treatment with standard treatment in near-term infants with moderate PPHN (alveolar-arterial oxygen gradient, (AaDO 2 ) of 500 to 599 torr), they found that iNO treatment improved PaO 2 , reduced the amount of ventilatory support and prevented progression to severe PPHN defined as AaDO 2 > 600 torr. Infants of the Control group also received iNO if their AaDO 2 was >600, there were no differences in need for ECMO or incidence of death. More recently, Konduri et al. 19 conducted a large randomized controlled multicenter trial in near-term infants who were <14 days old with moderate respiratory failure (OI of 15 to 25). They compared early use of iNO with a Control group that received simulated initiation of iNO. Infants received standard iNO if they developed an OI X25. Although the Early iNO group had significantly better initial oxygenation and Control group progressed to standard iNO and developed an OI >40 more often, the incidence of death, ECMO use and other respiratory outcomes was not different. Although this study evaluated a population similar to our study, controls had a lower threshold to receive standard iNO (OI >25) and ECMO was used as a back-up therapy. In addition, the mean OI at entry was approximately 20, which was close to the threshold to receive standard iNO. In fact, a significantly larger proportion of the control infants (54%) received standard iNO, and therefore there was not a clear separation between the Early and the Control groups that can explain the lack of a clear treatment effect. A subgroup analysis of the 176 infants enrolled at an OI of 15 to 20 in that study showed a trend for lower incidence of ECMO use/mortality (10% with Early iNO vs 18% in the Control group, P ¼ 0.12). 19, 20 Also, the incidence of ECMO use in the whole study (11%) was lower than that observed in previous large clinical trials with iNO (approximately 40%). Therefore, similar to our results, these data indicate that the earlier use of iNO may be associated with further reductions in short-term respiratory morbidity. There are several recently published studies that evaluated iNO treatment in premature infants. Although different strategies were evaluated and results are conflicting, it seems that early routine use in mildly sick ventilated preterm infants may improve their survival without bronchopulmonary dysplasia. [21] [22] [23] [24] This study also supports a possible beneficial effect of early iNO therapy in decreasing lung damage.
There are a number of factors that limit the impact of our trial. First, this trial was not blind because we had limited numbers of personnel and equipment to have independent teams masked to the assigned therapy or in charge of the iNO administration and monitoring. Second, this study took more than 5 years to be iNO in newborns with moderate respiratory failure A González et al completed, because of the difficulty in early recruitment of these patients and also because we had a limited and interrupted supply of nitric oxide during the study period. After the design and onset of this study, it became known that the use of HFOV improves the oxygenation response to iNO in newborns with hypoxic respiratory failure due to parenchymal lung disease. 25 However, because we had a limited availability of HFOV during the study period, this mode of ventilation was added to iNO only in infants who persist with severe respiratory failure (OI>40) despite the use of iNO.
Despite these limitations, we believe that the observed results in improved oxygenation and mitigation of the development of severe PPHN/respiratory failure (OI >40) with early iNO use are important, and support a strategy that may ameliorate the development of lung injury. Further studies are needed to confirm the impact of this strategy of iNO use in long-term respiratory outcomes.
